Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants
Potential risks including bruising, vein irritation, fluid overload, or rare allergic reactions are discussed during consultation, and suitability is confirmed before treatment
Tariq MA et al
this drug has recently completed phase 2a clinical trials with promising results in reducing HbA1c without any nausea [50]
Pharma Lab Global is a trusted supplier of peptides worldwide
